Milatuzumab

Research use only, not for human use.

Milatuzumab (MEDI-115) is a humanized monoclonal antibody against CD74. Milatuzumab promotes the production of free radical oxygen and the loss of mitochondrial membrane potential, reduces CD20/CD74 aggregates and cell adhesion, and induces cell death.

Milatuzumab (hLL1; MEDI-115) is a humanized anti-CD74 monoclonal antibody. CD74, a integral membrane protein, is associated with the promotion of B-cell growth and survival. Milatuzumab causes free radical oxygen generation, and loss of mitochondrial membrane potential. Milatuzumaba also decreases CD20/CD74 aggregates and cell adhesion, to lead to cell death.

Western Blot AnalysisCell Line:Jeko and Mino cells Concentration:5 μg/mL Incubation Time:4 hours Result:Insignificant down-regulation of antiapoptotic proteins, such as Bax, Bcl-2, Bcl-xL, and Mcl-1.Cell Viability Assay Cell Line:MCL cell lines and primarypatient tumor cells Concentration:5 μg/mL Incubation Time:8, 24, and 48 hoursResult:Resulted in cell death of Jeko, Mino, SP-53, Rec-1, HBL-2, and Granta cells. Immunofluorescence Cell Line:Jeko, Mino, and SP-53 cells Concentration:5 μg/mL; with or without 10 mM N-acetylcysteine (HY-B0215) for 1.5 h Incubation Time:0.5, 1, 1.5, and 2 hours Result:Increased ROS generation as early as 0.5 hours, while peaking at 1 to 1.5 hours and reducing at 2 hours.Therefore, it resulted cell death, but reserved by nonspecific ROS scavenger.

Animal Model:Jeko mouse model Dosage:15 mg/kg/day; with or without 15 mg/kg Rituximab Administration:Intraperitoneal injection; once every 3 days, starting at day 15 after engraftment Result:Resulted the mean survival for the combination treated group of 44.5 days, compared with 33.5 days for Milatuzumaba treated, 28 days for control.

——

Others

Other Targets

Others

——

——

899796-83-9

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years